
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.
The Ionis Pharmaceuticals Analyst: Jason Gerberry downgraded the rating for Ionis Pharmaceuticals from Buy to Underperform, while reducing the price target from $40 to $30.